| 10/06/2022 |
14:00 às 14:45 |
Módulo Câncer de Pele e Sarcomas |
14:00 às 14:05 |
9501 - Survival data of PRADO - A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma |
Palestrante |
| 10/06/2022 |
14:00 às 14:45 |
Módulo Câncer de Pele e Sarcomas |
14:05 às 14:10 |
LBA2 - Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). |
Palestrante |
| 10/06/2022 |
14:00 às 14:45 |
Módulo Câncer de Pele e Sarcomas |
14:10 às 14:15 |
11508 - Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG |
Palestrante |
| 10/06/2022 |
14:00 às 14:45 |
Módulo Câncer de Pele e Sarcomas |
14:30 às 14:45 |
Painel de discussão |
Debatedor |
